NCT04410796 - Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers | Biotech Hunter

Enrollment

571

Participants

Timeline

Start Date

May 28, 2020

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions

Metastatic Non-small Cell Lung Cancer

Interventions

DRUG

Osimertinib

80mg orally daily

DRUG

Carboplatin

Carboplatin (AUC 5 IV q 3 weeks)

DRUG

Pemetrexed

Pemetrexed (500mg/m2 IV q 3 weeks) for a total of 4 cycles

Trial Locations (18)

10010

RECRUITING

New York University, New York

10032

ACTIVE_NOT_RECRUITING

Columbia University (Data Collection Only), New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All protocol activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited protocol activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Commack (Limited protocol activities), Commack

21287

RECRUITING

John Hopkins Medical Center, Baltimore

33612

RECRUITING

Moffitt Cancer Center, Tampa

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

77030

RECRUITING

MD ANDERSON CANCER CENTER (Data Collection Only), Houston

94143

ACTIVE_NOT_RECRUITING

University of California San Francisco, San Francisco

95817

RECRUITING

UC Davis Cancer Center (Data Collection Only), Sacramento

98109

RECRUITING

University of Washington (Data Collection Only), Seattle

02114

RECRUITING

Massachusetts General Hospital (Data Collection Only), Boston

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07601

RECRUITING

Hackensack Meridian Health, Hackensack

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale